Pyxis Oncology (PYXS) Other Accumulated Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has reported Other Accumulated Expenses for 6 consecutive years, with $4.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Other Accumulated Expenses fell 37.2% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (down 37.2% YoY), while the FY2025 annual figure was $4.0 million, down 37.2% from the prior year.
• Other Accumulated Expenses eased to $4.0 million in Q4 2025 per PYXS's latest filing, from $6.4 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.4 million in Q4 2022 and bottomed at $356000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $6.1 million across 5 years, with a median of $4.0 million in 2025.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 97.96% — and 2024, when it soared 1687.92%.
• Pyxis Oncology's Other Accumulated Expenses stood at $2.4 million in 2021, then soared by 631.37% to $17.4 million in 2022, then slumped by 97.96% to $356000.0 in 2023, then jumped by 1687.92% to $6.4 million in 2024, then slumped by 37.2% to $4.0 million in 2025.
• Business Quant data shows PYXS's Other Accumulated Expenses at $4.0 million in Q4 2025, $6.4 million in Q4 2024, and $356000.0 in Q4 2023.